Search research articles
Contact Us
Filters
Showing results (21-30 of 24) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 24 results.
The Journal of Urology
|
September 22, 2018
Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder
Stefan De Wachter, Kevin D Benson, Roger R Dmochowski, et al.
The Journal of Urology
|
April 9, 2019
Re: Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder
Stefan De Wachter, Kevin D Benson, Roger R Dmochowski, et al.
Neuropharmacology
|
December 4, 2017
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease
Tom H Johnston, Eboo Versi, Patrick A Howson, et al.
Addiction Science & Clinical Practice
|
March 12, 2025
Lessons from the National institutes of health innovation corps program: defining barriers to developing and commercializing novel solutions for persons with opioid use disorder
Matthew P Heshmatipour, Tyler M Duvernay, Desislava Z Hite, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 24) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 24 results.
The Journal of Urology
|
September 22, 2018
Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder
Stefan De Wachter, Kevin D Benson, Roger R Dmochowski, et al.
The Journal of Urology
|
April 9, 2019
Re: Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder
Stefan De Wachter, Kevin D Benson, Roger R Dmochowski, et al.
Neuropharmacology
|
December 4, 2017
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease
Tom H Johnston, Eboo Versi, Patrick A Howson, et al.
Addiction Science & Clinical Practice
|
March 12, 2025
Lessons from the National institutes of health innovation corps program: defining barriers to developing and commercializing novel solutions for persons with opioid use disorder
Matthew P Heshmatipour, Tyler M Duvernay, Desislava Z Hite, et al.
Page
of 3